{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_names_stdName in Standardized Name (approximate match)
Status:
US Previously Marketed
Source:
CIBACALCIN by NOVARTIS
(1986)
Source URL:
First approved in 1986
Source:
CIBACALCIN by NOVARTIS
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125737
(2021)
Source URL:
First approved in 2021
Source:
BLA125737
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vintesomeran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:imelasomeran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT04470427: Phase 3 Interventional Completed SARS-CoV-2
(2020)
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
Moderna COVID-19 Vaccine by Moderna US, Inc.
(2023)
Source URL:
First approved in 2023
Source:
Moderna COVID-19 Vaccine by Moderna US, Inc.
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01621243: Phase 1/Phase 2 Interventional Terminated Metastatic Pancreatic Cancer
(2012)
Source URL:
Class:
POLYMER
